孕期糖尿病中的甲福明:使用或不使用,这是问题
Vera Tocci1,2, Maria Mirabelli1,2, Alessandro Salatino1
1Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
孕期糖尿病 (GDM) 在怀孕期间需要管理. 甲胺是一种胰岛素的替代品,但其对儿童的长期影响需要进一步研究.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 孕期糖尿病 (GDM) 在怀孕期间越来越多地被诊断为糖尿病.
- 在孕期内,GDM是由母亲的胰岛素抵抗引起的.
- 未经管理的GDM对母亲和孩子都有风险.
研究的目的:
- 审查目前关于甲福林用于GDM的证据.
- 为了澄清甲胺在GDM治疗中的益处和局限性.
- 为了帮助临床决策,关于甲福林的GDM.
主要方法:
- 在GDM怀孕中对甲福明的现有研究的文献综述.
- 对甲福林与胰岛素的安全性和疗效数据的分析.
- 评估有关甲福明的胎盘转移和对胎儿的潜在影响的证据.
主要成果:
- 甲胺被提议作为GDM的替代药理疗法.
- 对母亲来说,使用甲胺似乎是安全的.
- 人们担心甲素通过胎盘对婴儿的长期代谢影响.
结论:
- 甲胺为GDM管理提供了胰岛素的潜在替代品.
- 需要进一步的研究来解决关于子宫内甲福明暴露对儿童的长期影响的担忧.
- 临床医生需要全面的证据来指导对GDM的甲福林处方.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Pathophysiology of Diabetes
971
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
971
Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204
Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196


